# An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).

> **NCT01076010** · PHASE3 · COMPLETED · sponsor: **AVEO Pharmaceuticals, Inc.** · enrollment: 277 (actual)

## Conditions studied

- Advanced Renal Cell Carcinoma

## Interventions

- **DRUG:** Tivozanib
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01076010
- **Lead sponsor:** AVEO Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 277 (ACTUAL)
- **Last updated:** 2020-10-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076010, "An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01076010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*